Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290017 | 1.00 | KDM4E (0.54) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL30289878 | 0.84 | PYCR1 (0.51) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL46431 | 0.84 | PYCR1 (0.51) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL14097988 | 0.83 | SLC6A4 (0.46) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL8712410 | 0.82 | CCR5 (0.42) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL30036793 | 0.82 | KDM4E (0.56) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL31288205 | 0.82 | KDM4E (0.56) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL1990376 | 0.82 | KDM4E (0.56) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL3991296 | 0.82 | KDM4E (0.56) | KDM4ETDP1ALDH1A1MEN1MAPT | |
| SCHEMBL6093951 | 0.81 | KDM4E (0.51) | KDM4ETDP1ALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| CN-110546133-A | Anti-fibrotic compounds | SHIRE HUMAN GENETIC THERAPIES | 2019-12-06 | — | — | CN | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-6281359-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-08-28 | — | — | US | disclosed |
| US-6221871-B1 | TREATING SCHIZOPHRENIA, DEPRESSION OR PARKINSON'S DISEASE | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-5912350-A | Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands | NEUROGEN CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| US-5677454-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSONISM | NEUROGEN CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| US-5594141-A | ANTIPSYCHOTIC AND ANTIDEPRESSANT AGENTS; PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | KDM4E 4055/4885TDP1 3820/4885ALDH1A1 1274/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | KDM4E 4055/4885TDP1 3820/4885ALDH1A1 1274/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | KDM4E 4041/4885TDP1 3731/4885ALDH1A1 1184/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | KDM4E 3305/4885TDP1 3895/4885ALDH1A1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.